Gene · 1999
ELF3: E74 like ETS transcription factor 3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ELF3: E74 like ETS transcription factor 3. Genes, record 1999. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1999
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P78545 | ETS-related transcription factor Elf-3 | 371 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents39
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 44629 | P78545 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 44630 | P78545 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 44631 | P78545 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 7738 | P78545 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 14924 | P78545 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 7738 | P78545 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 14924 | P78545 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 14924 | P78545 | Espacenet |
| JP 2024109657 A | 2024-08-14 | 14763 | P78545 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 26446 | P78545 | Espacenet |
1 to 10 of 39
See all 39 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,571
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ELF3 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 15 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 15 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 8 | 2025 |
| UL1TR001881 | UCLA Clinical and Translational Science Institute | 5 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 4 | 2025 |
| P30CA036727 | Buffett Cancer Center Support Grant | 4 | 2025 |
| P30CA091842 | Cancer Center Support Grant | 4 | 2025 |
| P30DK034989 | Yale Liver Center | 4 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 4 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 1,571Source NIH's project files
See all 1,571 nih grantsPapers2,176
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Heterogeneous Radioimmunotherapy for Bulky Tumors: A Phase 1 Trial for Advanced Non-Small Cell Lung Cancer. | Adv Radiat Oncol | 2026 | 42824609 | PubTator, text mining | PubMed |
| Oral Actinobacteria sense and defend against parasitic epibionts. | bioRxiv | 2026 | 42818358 | PubTator, text mining | PubMed |
| Mapping Mutations and Signaling Network Interactions to Guide Precision Therapy in Gallbladder Cancer. | Cancer Rep (Hoboken) | 2026 | 42817222 | PubTator, text mining | PubMed |
| Episodic Future Thinking: A Behavioral Intervention to Promote Weight Loss in Breast Cancer Survivors (Alliance A21-Pilot10). | JCO Oncol Adv | 2026 | 42808090 | PubTator, text mining | PubMed |
| A canonical role of SMAD4 in safeguarding 3D genome architecture to suppress lung tumorigenesis. | Oncogene | 2026 | 42760353 | PubTator, text mining | PubMed |
| Target Antigen Identification for Antibody Drug Conjugate Therapy in Biliary Tract Cancer. | Clin Cancer Res | 2026 | 42720429 | PubTator, text mining | PubMed |
| A reproducible epithelial transcriptional state combines interferon-associated and secretory programs in pancreatic ductal adenocarcinoma. | Front Genet | 2026 | 42656570 | PubTator, text mining | PubMed |
| Integrative multi-omics analysis identifies an enhancer-driven ELF3-CLDN4 regulatory axis that shapes an immunosuppressive microenvironment and predicts prognosis in high-grade serous ovarian cancer. | Gene | 2026 | 42624178 | PubTator, text mining | PubMed |
| Construction and validation of a nomogram for the diagnosis of postmenopausal osteoporosis. | Mol Med Rep | 2026 | 42596822 | PubTator, text mining | PubMed |
| Super enhancer-driven transcriptional reprogramming promotes abiraterone resistance via neuroendocrine transition and ferroptosis evasion in castration-resistant prostate cancer. | Oncogene | 2026 | 42527507 | PubTator, text mining | PubMed |
1 to 10 of 2,176
See all 2,176 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1999
GET https://conductscience.org/api/genes/v1/1999/patents?page=2